Phase 1 Open-label Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an Immunomodulator and Tissue Repair Inducer, in Healthy Volunteers
Phase 1 open-label dose-escalation study to evaluate the safety and pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an immunomodulator and tissue repair inducer, in healthy volunteers.
100 项与 Immunalgia Therapeutics S.A. 相关的临床结果
0 项与 Immunalgia Therapeutics S.A. 相关的专利（医药）
100 项与 Immunalgia Therapeutics S.A. 相关的药物交易
100 项与 Immunalgia Therapeutics S.A. 相关的转化医学
